Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
Phase of Trial: Phase IV
Latest Information Update: 11 May 2017
At a glance
- Drugs Linagliptin (Primary) ; CD26 antigen inhibitors; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Jan 2017 Planned number of patients changed from 500000 to 99999.
- 16 Jun 2015 Planned number of patients changed from 250000 to 500000 as reported by ClinicalTrials.gov record.
- 04 Mar 2015 Planned number of patients changed from 200000 to 250000 as reported by ClinicalTrials.gov.